Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 9:16:1677-1685.
doi: 10.2147/COPD.S307164. eCollection 2021.

Factors Influencing the Length of Hospital Stay Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in Macao Population: A Retrospective Study of Inpatient Health Record

Meng Li #  1 , Kun Cheng #  2 , Keisun Ku  2 , Junlei Li  1 , Hao Hu  1 , Carolina Oi Lam Ung  1
Affiliations

Factors Influencing the Length of Hospital Stay Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in Macao Population: A Retrospective Study of Inpatient Health Record

Meng Li et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Purpose: This study aims to identify the effects of patient and clinical therapy factors on the length of hospital stay (LOS) for admission due to chronic obstructive pulmonary disease (COPD) in Macao.

Patients and methods: Health record of patients with COPD admitted to Kiang Wu Hospital from January 2017 to December 2019 was retrospectively analyzed. Demographic information, blood test results, clinical therapies, and LOS were described and analyzed by multivariable regression.

Results: A total of 1116 admissions were included with the average LOS being 12.28 (±9.23) days. Among them, 735 (66.6%) were male with mean age 79.42 (±10.35) years old, 697 were current or previous smokers (62.5%), and 360 (32.2%) had 3 or more comorbidities. During hospitalization, the most common treatments received were oxygen therapy (n=991,88.8%), antibiotics (n=828,74.2%), and systemic steroids (n=596,53.4%); only 120 (10.8%) had pulmonary rehabilitation (PR) and 128 (11.5%) received noninvasive ventilation (NIV). Inhaled medications were used during nearly 95% of hospitalization cases, while 2 and 3 types of inhaled medications were used during 230 (20.6%) and 582 (52.2%) hospitalization cases, respectively. Patient factors including age (B=0.178, 95% CI:0.535-1.072), being female (B=-1.147, 95% CI:-0.138-0.056), being current (B=-0.086, 95% CI:-0.124-0.018) or previous smoker (B=0.072, 95% CI:0.004-0.087), having 1, 2, 3 and over 3 comorbidities (B=0.126, 95% CI:0.034-0.147; B=0.125, 95% CI:0.031-0.144; B=0.116, 95% CI:0.028-0.146, B=0.090, 95% CI:0.021-0.166) and having low hemoglobin level (B=-0.118, 95% CI:-0.629- -0.214) exhibited significant associations with LOS. The use of NIV (B=0.080, 95% CI:0.022-0.138), pulmonary rehabilitation (B=0.269, 95% CI:0.212-0.327), two and three types of inhaled medications (B=0.109, 95% CI:0.003-0.166, B=0.255, 95% CI:0.083-0.237) were significantly associated with longer LOS (P<0.05).

Conclusion: NIV, PR and combined inhaled medications, which are often used for AECOPD, are the main clinical therapies associated with longer LOS in Macao. Smoking cessation, early treatments of comorbidities may be crucial to avoiding AECOPD and reducing LOS and disease burden.

Keywords: Macao; acute exacerbation; blood test results; chronic obstructive pulmonary disease; clinical therapy; inhaled medications; length of hospital stay.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Key steps of data analysis in this study.
See this image and copyright information in PMC

References

    1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi: 10.1164/rccm.201701-0218PP - DOI - PubMed
    1. Soriano JB, Abajobir AA, Abate KH; Collaborators GCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691. doi: 10.1016/S2213-2600(17)30293-X - DOI - PMC - PubMed
    1. Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387(10015):251–272. doi: 10.1016/S0140-6736(15)00551-6 - DOI - PubMed
    1. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] Study): a National Cross-Sectional Study. Lancet. 2018;391(10131):1706–1717. doi: 10.1016/S0140-6736(18)30841-9 - DOI - PubMed
    1. Zhu B, Wang Y, Ming J, Chen W, Zhang L. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:1353. doi: 10.2147/COPD.S161555 - DOI - PMC - PubMed